Business
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome 2024 XOLREMDI® net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through Conference call and webcast today at 8:30 am ET BOSTON, March 25, 2025 (GLOBE NEWSWIRE) --
About this update from X4 Pharmaceuticals, Inc.
[{"type":"image","alt":"X4 Pharmaceuticals","displaySize":"","headline":null,"caption":"X4 Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/beb74090cc798d5c3771a2fadf409727"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sgkmhEK6I7T7bbBXoDPp1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/beb74090cc798d5c3771a2fadf409727","width":210,"height":140}},"lazy":false},{"type":"text","content":"Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026","length":174,"tagName":"p"},{"type":"text","content":"4WARD trial protocol refined, increasing confidence in successful outcome ","length":73,"tagName":"p"},{"type":"text","content":"2024 XOLREMDI® net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through","length":164,"tagName":"p"},{"type":"text","content":"Conference call and webcast today at 8:30 am ET","length":47,"tagName":"p"},{"type":"text","content":"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted key 2024 and recent events and expected upcoming milestones.","length":338,"tagName":"p"},{"type":"text","content":"“As expected, 2024 was a transformative year for the company and our momentum has continued into 2025,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “With the U.S. approval and launch of our first product, XOLREMDI® (mavorixafor) in WHIM syndrome, we are now a fully integrated company advancing our mission to serve those with rare immunodeficiencies and few treatment options. As we await word from the EU regulatory authority on the potential approval of mavorixafor for WHIM in that region, we’ve continued to expand our potential reach to the global WHIM community through our recently completed commercialization partnerships in the EU, Australia, New Zealand, and the Middle East and North Africa (MENA) territories.”",...